Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ceconomy AG meldet starkes Umsatz- und EBIT-Wachstum für Q4 2025 (Investing.com DE) +++ CECONOMY Aktie -3,30%

IDEAYA Aktie

 >IDEAYA Aktienkurs 
28.9 EUR    (Tradegate)
Ask: 29 EUR / 103 Stück
Bid: 28.8 EUR / 106 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IDEAYA Aktie über LYNX handeln
>IDEAYA Performance
1 Woche: -3,4%
1 Monat: 0%
3 Monate: +36,5%
6 Monate: +48,7%
1 Jahr: +17,4%
laufendes Jahr: +17,8%
>IDEAYA Aktie
Name:  IDEAYA BIOSCIENCE DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45166A1025 / A2PJPB
Symbol/ Ticker:  30J (Frankfurt) / IDYA (NASDAQ)
Kürzel:  FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA
Index:  -
Webseite:  https://www.ideayabio.com..
Profil:  Ideaya Biosciences Inc. is a biotechnology company..
>Volltext..
Marktkapitalisierung:  2505.99 Mio. EUR
Unternehmenswert:  1858.85 Mio. EUR
Umsatz:  182.99 Mio. EUR
EBITDA:  -174.48 Mio. EUR
Nettogewinn:  -136.91 Mio. EUR
Gewinn je Aktie:  -1.57 EUR
Schulden:  23.21 Mio. EUR
Liquide Mittel:  254.62 Mio. EUR
Operativer Cashflow:  -87.1 Mio. EUR
Bargeldquote:  12.2
Umsatzwachstum:  5096.12%
Gewinnwachstum:  14.38%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IDEAYA
Letzte Datenerhebung:  17.12.25
>IDEAYA Kennzahlen
Aktien/ Unternehmen:
Aktien: 87.67 Mio. St.
Frei handelbar: 95.58%
Rückkaufquote: -1.03%
Mitarbeiter: 131
Umsatz/Mitarb.: 0.05 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 48.15%
Bewertung:
KGV: -
KGV lG: -
KUV: 14.31
KBV: 2.71
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 98.12%
Gewinnmarge: -74.82%
Operative Marge: -97.23%
Managementeffizenz:
Gesamtkaprendite: -13.26%
Eigenkaprendite: -14.15%
>IDEAYA Peer Group

Es sind 599 Aktien bekannt.
 
11.12.25 - 12:03
 IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire)
 
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States SOUTH SAN FRANCISCO, Calif., Dec. 11,......
10.12.25 - 12:03
 IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers (PR Newswire)
 
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025......
05.12.25 - 23:06
 GSK ends collaboration with IDEAYA for two candidates (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.12.25 - 14:36
 IDEAYA Biosciences: FDA-Zulassung für Krebsmedikament treibt Aktie an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
01.12.25 - 12:02
 IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types (PR Newswire)
 
B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively Deep and durable regressions observed with IDE034 monotherapy in multiple preclinical in-vivo models with B7H3 and PTK7......
28.11.25 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 26, 2025, the Compensation Committee of IDEAYA's......
24.11.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Citi's 2025......
04.11.25 - 12:27
 IDEAYA Biosciences GAAP EPS of $1.33, revenue of $207.83M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.11.25 - 12:03
 IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
 
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end 21.1 month median OS and 7.0 month median PFS reported from......
31.10.25 - 11:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 30, 2025, the Compensation Committee of IDEAYA's......
27.10.25 - 11:03
 IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Citi's 2025......
20.10.25 - 15:12
 Positive Studiendaten zu Augenkrebs-Medikament treiben Aktie von Ideaya Biosciences an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.10.25 - 12:33
 IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 (PR Newswire)
 
83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% ocular tumor shrinkage 70% (26/37) of plaque......
20.10.25 - 12:02
 IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
 
Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting Median progression free survival (PFS) of 7.0 months Confirmed overall......
26.09.25 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 25, 2025, the Compensation Committee of......
08.09.25 - 12:06
 IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma (PR Newswire)
 
Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in the neoadjuvant setting of primary uveal melanoma Manageable safety profile with mostly......
07.09.25 - 18:06
 IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer (PR Newswire)
 
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE849 77.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending......
04.09.25 - 16:30
 Ideaya Biosciences gets coverage initiation at Barclays and Citizens (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.09.25 - 12:03
 IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of......
03.09.25 - 12:02
 IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PR Newswire)
 
Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A inhibitor, will be presented at the 10-Year Anniversary R&D Day on September 8th SOUTH SAN......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!